Founded in 2009 at the HudsonAlpha Institute for Biotechnology, iRepertoire pioneered the commercialization of NGS based immune repertoire sequencing of T and B Cells, the biological frontline defense from disease and infections.
The AIRR (Adaptive Immune Receptor Repertoire) is a critical biomarker for understanding both individual historical exposure to infections and vaccines as well as the onset of autoimmune diseases and cancer. As part of the emerging multi-omics landscape, the AIRR is essential for development of a wide range of novel therapeutics including cell therapies, antibody drug conjugates, and mRNA vaccines. The AIRR also holds the potential to be leveraged as a universal indicator of health.
iRepertoire’s services are uniquely positioned to capture all seven TCR and BCR chains for a comprehensive picture of the immune system status. This allows for detailed treatment response tracking and improved patient outcomes.
At iRepertoire, scientific collaboration, curiosity, and innovation drive us. Our close-knit team fosters a creative, hands-on culture that supports both scientific breakthroughs and meaningful partnerships.
